![Marco Weibel](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ursprung des Netzwerks ersten Grades von Marco Weibel
Einheit | Art der Einheit | Industrie | |
---|---|---|---|
Nextech Invest AG
![]() Nextech Invest AG Investment ManagersFinance Nextech Invest AG (Nextech) is an independent venture capital firm with headquarters in Zurich, Switzerland. It was founded by Alfred Scheidegger in 1998. Nextech's investors include public pension funds, banks, asset management companies and Swiss and German high-net worth individuals.
18
| Private Company | Investment Managers | 18 |
Unternehmensgrafik - zweiten Grades
Beziehungen zu mehreren Unternehmen
Unternehmensverbindungen über das persönliche Netzwerk von Marco Weibel
Unternehmen | Sektor | Verknüpfte Personen | Hauptposition |
---|---|---|---|
ImaginAb, Inc.
![]() ImaginAb, Inc. Medical SpecialtiesHealth Technology ImaginAb, Inc. develops engineered antibody fragments for diagnostic imaging and novel therapeutic applications. It products offer actionable data to facilitate diagnosis of disease, inform better treatment decisions, and monitor response to therapy. The firm also offers a range of pre-clinical (animal imaging) reagents for use with microPET, microSPECT, and optical imaging systems. The company was founded by Christian P. Behrenbruch, Tove Olafsen, Anna M. Wu, and Robert E. Reiter in 2007 and is headquartered in Inglewood, CA. | Medical Specialties | Director/Board Member Director/Board Member | |
University of Basel | College/University | Undergraduate Degree Doctorate Degree | |
TRACON PHARMACEUTICALS, INC. | Pharmaceuticals: Major | Director/Board Member Corporate Officer/Principal | |
The Genetics Co., Inc.
![]() The Genetics Co., Inc. Medical/Nursing ServicesHealth Services The Genetics Company is a privately held drug discovery and development company active in the areas of cancer and neurodegenerative diseases. The company has identified small molecule inhibitors of two proprietary targets with in the Wnt-pathway, which is believed to play a crucial role in colon cancer. It has also identified small molecule inhibitors of BACE (beta-amyloid converting enzyme). In parallel, the company has identified and is in the process of further characterizing a series of novel growth-related drug target candidate genes for exploitation in cancer therapy. Headquartered in Zurich-Schlieren, Switzerland, the company currently has 29 employees. The Genetics Company offers you a range of high quality products to analyze Amyloid beta peptides x-40 and x-42 for basic research but also for pre-clinical and clinical development and in vitro diagnostics (IVD). Its CE-certified ELISA kits are the only clinically validated products for the determination of the Abeta42/40-Ratio in human CSF. These kits enable the early diagnosis of incipient Alzheimer's disease and can be used for patient stratification and monitoring in clinical trials of Alzheimer drug candidates. | Medical/Nursing Services | Director/Board Member Chairman | |
REVOLUTION MEDICINES, INC. | Pharmaceuticals: Other | Director/Board Member | |
MOMA Therapeutics, Inc.
![]() MOMA Therapeutics, Inc. BiotechnologyHealth Technology MOMA Therapeutics, Inc. operates as a biotechnology firm. The company was founded by Dorothee Kern, Eva Nogales, Johannes Walter, and Timur Yusufzai and is headquartered in Cambridge, MA. | Biotechnology | Director/Board Member | |
BLACK DIAMOND THERAPEUTICS, INC. | Biotechnology | Director/Board Member | |
Circle Pharma, Inc.
![]() Circle Pharma, Inc. BiotechnologyHealth Technology Circle Pharma, Inc. provides biotechnology services. The company was founded by Matthew P. Jacobson and Scott Lokey in June 2014 and is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member | |
PMV PHARMACEUTICALS, INC. | Miscellaneous Commercial Services | Director/Board Member | |
PELOTON THERAPEUTICS, INC. | Pharmaceuticals: Major | Director/Board Member | |
IDEAYA BIOSCIENCES, INC. | Pharmaceuticals: Major | Director/Board Member | |
Alterome Therapeutics, Inc.
![]() Alterome Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Alterome Therapeutics, Inc. is a precision oncology biotech that develops alteration-specific therapeutics to address high-value and validated oncogenic drivers. The company is based in San Marcos, CA. The company is led by seasoned R&D leaders with a history of developing marketed oncology small molecule drugs. The company's mission is to discover precise therapies and inspire hope for individuals affected by cancer. The CEO of the company is Eric A. Murphy. | Pharmaceuticals: Major | Director/Board Member | |
Amgen Ltd.
![]() Amgen Ltd. Miscellaneous Commercial ServicesCommercial Services Amgen Ltd. operates as a biotechnology firm. It engages in the research and development of human therapeutics to treat illnesses. The company was founded on March 1, 1989 and is headquartered in Cambridge, the United Kingdom. | Miscellaneous Commercial Services | Corporate Officer/Principal | |
Ecole Supérieure de Technologie des Biomolécules de Bordeaux | College/University | Graduate Degree | |
University of Zurich | College/University | Doctorate Degree | |
Technische Universität Darmstadt | College/University | Undergraduate Degree | |
BLUEPRINT MEDICINES CORPORATION | Biotechnology | Director/Board Member | |
Wemedoo AG | Chairman | ||
8stogg AG | Director/Board Member | ||
Swiss Federal Institute of Technology | College/University | Chief Administrative Officer | |
Exo Therapeutics, Inc.
![]() Exo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Exo Therapeutics, Inc. engages in production of drugs. It has developed a small-molecule enzyme inhibitor discovery platform that targets distal binding pockets of enzymes (exo-sites) that are not evolutionarily conserved. The company was founded by David R. Liu and Alan Saghatelian and is headquartered in Boston, MA. | Pharmaceuticals: Major | Director/Board Member | |
RELAY THERAPEUTICS, INC. | Biotechnology | Founder | |
Nextech Venture Principals Ltd.
![]() Nextech Venture Principals Ltd. Financial ConglomeratesFinance Nextech Venture Principals Ltd. provides investment services. The private company is based in Jersey. | Financial Conglomerates | Director/Board Member | |
Flare Therapeutics, Inc.
![]() Flare Therapeutics, Inc. BiotechnologyHealth Technology Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022. | Biotechnology | Director/Board Member | |
University of California, Los Angeles | College/University | Doctorate Degree | |
Alpha-9 Oncology, Inc.
![]() Alpha-9 Oncology, Inc. Miscellaneous Commercial ServicesCommercial Services Alpha-9 Theranostics, Inc. operates as a clinical stage radiopharmaceutical company. It engages in developing breakthrough targeting agents for cancer imaging by positron emission tomography (PET) and therapy using targeted radioisotopes. The company was founded by Fran?ois B?nard, David Perrin, Kuo-Shyan Lin, and Ian McBeath and is headquartered in Vancouver, Canada. | Miscellaneous Commercial Services | Director/Board Member | |
Ambagon Therapeutics, Inc.
![]() Ambagon Therapeutics, Inc. BiotechnologyHealth Technology Ambagon Therapeutics, Inc. provides healthcare services. It specializes in biotechnology. The company is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member | |
TYRA BIOSCIENCES, INC. | Biotechnology | Director/Board Member | |
Hexagon Bio, Inc.
![]() Hexagon Bio, Inc. BiotechnologyHealth Technology Hexagon Bio, Inc. operates as a data-driven biotechnology company. It engages in mining of fungal genome data for drugs. The company was founded by Maureen E. Hillenmeyer, Brian T. Naughton, Colin James Bell Harvey and Yi Tang and is headquartered in Menlo Park, CA. | Biotechnology | Director/Board Member | |
AUTOLUS THERAPEUTICS PLC | Biotechnology | Director/Board Member | |
BOUNDLESS BIO, INC. | Biotechnology | Director/Board Member | |
TURG POIN | Pharmaceuticals: Major | Director/Board Member | |
KINNATE BIOPHARMA INC. | Pharmaceuticals: Major | Director/Board Member | |
IconOVir Bio, Inc.
![]() IconOVir Bio, Inc. BiotechnologyHealth Technology IconOVir Bio, Inc. is an American biotechnology company that operates in the field of life sciences. The company was founded in 2018 by Arie S. Belldegrun, Ben Stone. The CEO is Mark A. McCamish. | Biotechnology | Director/Board Member | |
Arvinas Operations, Inc.
![]() Arvinas Operations, Inc. BiotechnologyHealth Technology Arvinas Operations, Inc. develops novel therapeutics for the treatment of cancer, pro-inflammatory, autoimmune and rare diseases. It offers proteolysis-targeting chimera PROTAC-based drugs that induce protein degradation to target and eliminate disease-causing proteins from the body. The company was founded by Craig M. Crews in July 2013 and is headquartered in New Haven, CT. | Biotechnology | Director/Board Member | |
KRONOS BIO, INC. | Pharmaceuticals: Major | Director/Board Member | |
SYROS PHARMACEUTICALS, INC. | Biotechnology | Founder | |
Vividion Therapeutics, Inc.
![]() Vividion Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Vividion Therapeutics, Inc. operates as a biotechnology company. The company focuses on developing innovative therapeutics that treat major unmet clinical needs using the first platform for proteome wide drug and target discovery. It's proprietary chemoproteomic platform technology addresses the key limitations of conventional screening techniques and allows the discovery of previously unknown, or cryptic, functional pockets on the surface of proteins and identification of small molecules that selectively bind to those targets. The company was founded by Benjamin F. Cravatt, Phil S. Baran, Jin-Quan Yu and John K. Clarke on December 24, 2013 and is headquartered in San Diego, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Arrakis Therapeutics, Inc.
![]() Arrakis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA. | Pharmaceuticals: Major | Director/Board Member | |
Third Rock Ventures LLC
![]() Third Rock Ventures LLC Investment ManagersFinance Third Rock Ventures LLC (Third Rock Ventures) is a venture capital firm founded in 2007 by Mark Levin, Robert Tepper, Kevin Starr and Nick Leschly. The firm is headquartered in Boston, Massachusetts. | Investment Managers | Corporate Officer/Principal | |
Karolinska Institutet | College/University | Doctorate Degree | |
University of Anglia Ruskin | College/University | Undergraduate Degree | |
ARVINAS, INC. | Biotechnology | Director/Board Member | |
A2 Biotherapeutics, Inc.
![]() A2 Biotherapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services A2 Biotherapeutics, Inc. operates as a biotechnology company. It develops medicines. The company was founded by Alexander Kamb, Michael Gallo and Paul Kang in 2018 and is headquartered in Westlake Village, CA. | Miscellaneous Commercial Services | Director/Board Member | |
Rising Tide Foundation | Investment Trusts/Mutual Funds | Director/Board Member | |
Cleave Therapeutics, Inc.
![]() Cleave Therapeutics, Inc. BiotechnologyHealth Technology Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA. | Biotechnology | Director/Board Member | |
Swiss Scientific Computing Center
![]() Swiss Scientific Computing Center Miscellaneous Commercial ServicesCommercial Services The Swiss Scientific Computing Center develops and provides supercomputing capabilities to solve important problems in science and society. The private company is based in Manno, Switzerland. | Miscellaneous Commercial Services | Chief Executive Officer |
Statistik
International
Vereinigte Staaten | 34 |
Schweiz | 8 |
Deutschland | 4 |
Vereinigtes Königreich | 4 |
Frankreich | 2 |
Sektoral
Health Technology | 29 |
Consumer Services | 9 |
Commercial Services | 7 |
Finance | 4 |
Miscellaneous | 3 |
Operativ
Director/Board Member | 64 |
Independent Dir/Board Member | 11 |
Private Equity Analyst | 9 |
Corporate Officer/Principal | 9 |
Private Equity Investor | 9 |
Am stärksten vernetzte Beziehungen
- Börse
- Insiders
- Marco Weibel
- Unternehmensverbindungen